 The pharmacokinetic and pharmacodynamic profile of insulin aspart will be derived from the time-action profiles of insulin and glucose, respectively, in response to insulin in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmoll calculated by the insulin-sensitivity factor after reaching hyperglycemia 18-23 mmoll. All patients will be investigated twice, where on one occasion the jet-injector device will be used to inject insulin, and on the other occasion insulin will be injected with a conventional insulin pen. The order of these occasions will be randomised. Both devices will be operated by the patient after sufficient training. Ease of use will be evaluated. 